Medical - Healthcare Plans · NYSE
Current Price
$389.91
Intrinsic Value
Outside reliable range
The base-case DCF model produces an intrinsic value estimate for Humana Inc. (HUM) that falls outside its reliable range, so treat any single number with extra caution. This usually happens with unusual cash flow patterns or rapid recent changes in the business.
How the DCF works · Recalculate with your own assumptions · What is intrinsic value?
Because the model output for HUM is outside the reliable range, no undervalued or overvalued read is given here. Use the calculator below to test your own assumptions instead.
COMPETITIVE MOAT
INVESTMENT RISKS
Base case
Base case assumptions: 6.9% annual growth, 10.0% discount rate, 30x exit multiple, 5 year projection. Data as of 2026-11-20.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for Humana Inc. respond.
Open DCF Calculator for HUMHumana Inc., a prominent health and well-being enterprise, operates across the United States through its various subsidiary companies. Its operational structure is divided into three main segments: Retail, Group and Specialty, and Healthcare Services. The firm provides a wide array of medical and supplementary insurance plans directly to individual consumers. Furthermore, Humana collaborates with government entities; it holds a contract with the Centers for Medicare and Medicaid Services (CMS) to manage the Limited Income Newly Eligible Transition (LI NET) prescription drug program. The company also secures agreements with numerous states to deliver Medicaid, dual-eligible, and long-term care support benefits. For employer groups and individuals, Humana furnishes fully insured commercial medical and specialized health coverage, which encompasses dental, vision, and other ancillary health benefits. They additionally offer administrative services only (ASO) solutions and extend support to military personnel through contracts like the TRICARE T2017 East Region. Beyond insurance products, the company delivers comprehensive healthcare services directly. These include pharmacy management, provider network services, and a suite of home-based solutions such as home health care, serving both its own health plan enrollees and external clients. By the close of 2021 (December 31), Humana's reach extended to approximately 17 million individuals enrolled in its medical benefit plans and an additional 5 million utilizing its specialized product offerings. Established in 1961, Humana Inc. maintains its corporate headquarters in Louisville, Kentucky.
Revenue/Share (TTM)
$1283.87
FCF/Share (TTM)
$6.22
ROIC (TTM)
4.4%
ROE (TTM)
6.7%
P/FCF
62.7x
EV/EBITDA
16.2x
FCF Yield
1.60%
Debt/Equity
0.66x
Based on trailing twelve-month data, HUM shows a free cash flow per share of $6.22 and a ROIC of 4.4%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 62.7x and FCF yield of 1.60% are important context metrics when evaluating HUM's stock valuation relative to peers.
Humana Inc. currently generates $6.22 in free cash flow per share. At the current price of $389.91, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
HUM trades at a P/FCF ratio of 62.7x with a free cash flow yield of 1.60%. A high P/FCF means investors are paying more per dollar of free cash flow, which usually reflects expectations of future growth. However, whether HUM is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
To perform a DCF valuation on Humana Inc.: (1) Start with the trailing free cash flow per share ($6.22) as the base, (2) project future FCF growth over 5-10 years based on Medical - Healthcare Plans industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting HUM's risk profile — with a debt-to-equity of 0.66x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For Humana Inc., this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Medical - Healthcare Plans trends, then discounting those amounts to today's dollars. HUM's ROIC of 4.4% means the company's return on invested capital sits below the level that typically clears its cost of capital.
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For HUM, with a debt-to-equity ratio of 0.66x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of 16.2x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
DCF and P/E value HUM with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-11-20. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.